# Cerebral hemodynamic impairment in symptomatic and asymptomatic Alzheimer's Disease

> **NIH NIH R01** · EMORY UNIVERSITY · 2022 · $857,527

## Abstract

Abstract
Alzheimer's Disease (AD) is rapidly becoming an overwhelming economic and social burden. It is estimated
that 13.8 million Americans will have AD in 2050 and the total annual payments for health, long-term, and
hospice care for AD and other dementias will increase to $1.2 trillion in 2050. Despite the important role of
cerebrovascular function in AD, studies on cerebrovascular impairment in the asymptomatic phase of AD are
lacking. The proposed project directly addresses this important scientific area by using advanced MR imaging
techniques to study biomarkers of cerebrovascular function in AD subjects both before and after the
manifestation of clinical symptoms. The overarching goal of the proposed project is to study whether AD
pathology directly interacts with cerebrovascular pathology in the early phases of the AD continuum, as well as
the relative contributions of cerebrovascular and AD pathologies to cognitive impairments in early AD. (1) We
will use an advanced MR technique for measuring cerebrovascular reactivity (CVR) as a biomarker of vascular
function and study CVR in 264 subjects composed of four groups including healthy young and middle-aged
subjects (HY), cognitive normal elderly without AD pathology (CN-), asymptomatic AD subjects who are
cognitively normal with positive AD pathology (aAD), and prodromal AD patients who are symptomatic with
mild cognitive impairment and have positive AD pathology (pAD). Longitudinal changes in CVR over two years
in CN-, aAD, and pAD subjects will also be studied. (2) We will also study differences in the white matter
hyperintensity volume and advanced diffusion metrics between the CN-, aAD, and pAD groups, their
longitudinal changes and relationship with CVR. (3) The relative contributions of AD and vascular pathologies
to cognitive performance will also be evaluated. The successful execution of the study will provide a better
understanding of the interactions between AD pathology and cerebrovascular dysfunction in the early phases
of AD continuum that could eventually lead to the development of effective multi-component therapeutic
interventions of AD that target both AD and vascular pathologies.

## Key facts

- **NIH application ID:** 10370529
- **Project number:** 1R01AG072603-01A1
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Deqiang Qiu
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $857,527
- **Award type:** 1
- **Project period:** 2022-02-01 → 2027-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10370529

## Citation

> US National Institutes of Health, RePORTER application 10370529, Cerebral hemodynamic impairment in symptomatic and asymptomatic Alzheimer's Disease (1R01AG072603-01A1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10370529. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*